News & views: anti-amyloid antibodies and novel emerging approaches to Alzheimer’s disease in 2023

News & views: anti-amyloid antibodies and novel emerging approaches to Alzheimer’s disease in 2023

Bibliographic Details
Main Author:	Sam Gandy
Format:	Article
Language:	English
Published:	BMC 2023-09-01
Series:	Molecular Neurodegeneration
Subjects:	Aducanumab Bapineuzumab Donanemab Lecanemab
Online Access:	https://doi.org/10.1186/s13024-023-00656-x

Similar Items

Talking points for physicians, patients and caregivers considering Aduhelm® infusion and the accelerated pathway for its approval by the FDA
by: Sam Gandy, et al.
Published: (2021-11-01)

Development of monoclonal antibody therapeutics for alzheimer's disease
by: Masatoshi Takeda
Published: (2022-01-01)

Aducanumab and lecanemab – two novel antibodies against pathologic species of amyloid beta in the treatment of Alzheimer’s disease
by: Jakub Wojcieszak
Published: (2023-05-01)

Immunotherapies Targeting Amyloid and Tau Protein in Alzheimer’s Disease: Should We Move Away from Diseases and Focus on Biological Targets? A Systematic Review and Expert Opinion
by: Arthur Esquer, et al.
Published: (2023-10-01)

Impact of Anti-amyloid-β Monoclonal Antibodies on the Pathology and Clinical Profile of Alzheimer’s Disease: A Focus on Aducanumab and Lecanemab
by: Mingchao Shi, et al.
Published: (2022-04-01)

The FDA-approved anti-amyloid-β monoclonal antibodies for the treatment of Alzheimer’s disease: a systematic review and meta-analysis of randomized controlled trials
by: Wenxue Wu, et al.
Published: (2023-11-01)

Neurotoxic Soluble Amyloid Oligomers Drive Alzheimer’s Pathogenesis and Represent a Clinically Validated Target for Slowing Disease Progression
by: Martin Tolar, et al.
Published: (2021-06-01)

Bapineuzumab for mild to moderate Alzheimer’s disease: a meta-analysis of randomized controlled trials
by: Abdelrahman Ibrahim Abushouk, et al.
Published: (2017-04-01)

Amyloid-Related Imaging Abnormalities With Anti-amyloid Antibodies for the Treatment of Dementia Due to Alzheimer's Disease
by: Charles G. Withington, et al.
Published: (2022-03-01)

Donanemab for Alzheimer’s Disease: A Systematic Review of Clinical Trials
by: Areeba Rashad, et al.
Published: (2022-12-01)

Donanemab (LY3002813) dose‐escalation study in Alzheimer's disease
by: Stephen Loucian Lowe, et al.
Published: (2021-01-01)

Lecanemab: A Second in Class Therapy for the Management of Early Alzheimer’s Disease
by: Connie Yoon, et al.
Published: (2024-03-01)

Advancing Alzheimer’s care: a novel therapy with lecanemab
by: Advait Teli, et al.
Published: (2023-11-01)

Revisiting the Amyloid Cascade Hypothesis: From Anti-Aβ Therapeutics to Auspicious New Ways for Alzheimer’s Disease
by: Md. Sahab Uddin, et al.
Published: (2020-08-01)

A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody
by: Chad J. Swanson, et al.
Published: (2021-04-01)

Beyond lecanemab: Examining Phase III potential in Alzheimer's therapeutics
by: Hitoshi Osaka, et al.
Published: (2024-03-01)

Cost‐effectiveness of aducanumab to prevent Alzheimer's disease progression at current list price
by: Pranay Sinha, et al.
Published: (2022-01-01)

Impacts of FDA approval and Medicare restriction on antiamyloid therapies for Alzheimer's disease: patient outcomes, healthcare costs, and drug development
by: Rouen Brockmann, et al.
Published: (2023-04-01)

The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer's disease: an EADC-EC viewpoint
by: Linus Jönsson, et al.
Published: (2023-06-01)

Aducanumab—Hope or Disappointment for Alzheimer’s Disease
by: Karolina Wojtunik-Kulesza, et al.
Published: (2023-02-01)

A light at the end of the tunnel – from mutation identification to a potential treatment for Alzheimer’s disease
by: Lars Lannfelt
Published: (2023-11-01)

Mini review: Prospective therapeutic targets of Alzheimer's disease
by: RuchiMangal, et al.
Published: (2022-01-01)

Is Aducanumab treatment developed to prevent progression of Alzheimer's disease cost-effective in Turkey?
by: Vahit Yigit, et al.
Published: (2023-08-01)

Neurodegenerative diseases: from gut-brain axis to brain microbiome
by: Robert P. Friedland, et al.
Published: (2023-05-01)

Therapeutic Ultrasound as a Treatment Modality for Physiological and Pathological Ageing Including Alzheimer’s Disease
by: Jürgen Götz, et al.
Published: (2021-07-01)

Aducanumab and Its Effects on Tau Pathology: Is This the Turning Point of Amyloid Hypothesis?
by: Serena Silvestro, et al.
Published: (2022-02-01)

ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer's disease
by: Lawrence S. Honig, et al.
Published: (2023-01-01)

Safety and efficacy of lecanemab for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials
by: Yue Qiao, et al.
Published: (2023-05-01)

A Path to Improved Alzheimer’s Care: Simulating Long-Term Health Outcomes of Lecanemab in Early Alzheimer’s Disease from the CLARITY AD Trial
by: Amir Abbas Tahami Monfared, et al.
Published: (2023-04-01)

A how-to guide for a precision medicine approach to the diagnosis and treatment of Alzheimer's disease
by: Gayatri Devi, et al.
Published: (2023-08-01)

Imaging spectrum of amyloid-related imaging abnormalities associated with aducanumab immunotherapy
by: Houman Sotoudeh, et al.
Published: (2024-01-01)

Targeting the molecular web of Alzheimer’s disease: unveiling pathways for effective pharmacotherapy
by: Devika Jadhav, et al.
Published: (2024-01-01)

Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease in the Era of Disease-Modifying Treatments
by: George P. Paraskevas, et al.
Published: (2021-09-01)

Symptomatic amyloid‐related imaging abnormalities in an APOE ε4/ε4 patient treated with aducanumab
by: Lawren VandeVrede, et al.
Published: (2020-01-01)

Donanemab exposure and efficacy relationship using modeling in Alzheimer's disease
by: Ivelina Gueorguieva, et al.
Published: (2023-04-01)

Enhanced delivery of a low dose of aducanumab via FUS in 5×FAD mice, an AD model
by: Chanho Kong, et al.
Published: (2022-12-01)

The search for clarity regarding “clinically meaningful outcomes” in Alzheimer disease clinical trials: CLARITY-AD and Beyond
by: Rawan Tarawneh, et al.
Published: (2024-02-01)

Alzheimer's disease drug development pipeline: 2022
by: Jeffrey Cummings, et al.
Published: (2022-01-01)

Aducanumab: A new hope in Alzheimer's disease
by: Rouchan Ali, et al.
Published: (2022-09-01)

Effects of dose change on the success of clinical trials
by: Guogen Shan, et al.
Published: (2022-12-01)